Evidence map›Paper›PMID 42402534›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

The preventable burden of tobacco-attributable cancer incidence in Catalonia (Spain) in 2024: a Bayesian approach.

Ramon Clèries, Joan Martínez, Alberto Ameijide, Jan Trallero, Arantza Sanvicens, Isaac Torres, Marià Carulla, Maria Buxó, Josep Alfons Espinàs, Pere Godoy and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ramon ClèriesPla Director d'Oncologia - Institut Català d'Oncologia, Av Gran Vía 199-203, 08908, L'Hospitalet de Llobregat (Barcelona), Spain. r.cleries@iconcologia.net.ORCID http://orcid.org/0000-0002-3637-4747
Joan MartínezGirona Biomedical Research Institute, IDIBGI, Parc Hospitalari Martí I Julià, C/Dr. Castany s/n, Edifici M2, 17190, Salt, Spain.
Alberto AmeijideRegistre de Càncer de Tarragona, Servei d'Epidemiologia I Prevenció del Càncer, Hospital Universitari Sant Joan de Reus, IISPV, Reus, Spain.
Jan TralleroRegistre de Càncer de Girona-Unitat d'Epidemiologia, Pla Director d'Oncologia, Institut Català d'Oncologia, Grup d'Epidemiologia Descriptiva, Genètica i Prevenció del Càncer de Girona-IDIBGI, 17005, Girona, Spain.
Arantza SanvicensRegistre de Càncer de Girona-Unitat d'Epidemiologia, Pla Director d'Oncologia, Institut Català d'Oncologia, Grup d'Epidemiologia Descriptiva, Genètica i Prevenció del Càncer de Girona-IDIBGI, 17005, Girona, Spain.
Isaac TorresRegistre de Càncer de Lleida, Av. Alcalde Rovira Roure 44, 25198, Lleida, Spain.
Marià CarullaRegistre de Càncer de Tarragona, Servei d'Epidemiologia I Prevenció del Càncer, Hospital Universitari Sant Joan de Reus, IISPV, Reus, Spain.
Maria BuxóGirona Biomedical Research Institute, IDIBGI, Parc Hospitalari Martí I Julià, C/Dr. Castany s/n, Edifici M2, 17190, Salt, Spain.
Josep Alfons EspinàsPla Director d'Oncologia - Institut Català d'Oncologia, Av Gran Vía 199-203, 08908, L'Hospitalet de Llobregat (Barcelona), Spain.
Pere GodoyRegistre de Càncer de Lleida, Av. Alcalde Rovira Roure 44, 25198, Lleida, Spain.
Rafael Marcos-GrageraRegistre de Càncer de Girona-Unitat d'Epidemiologia, Pla Director d'Oncologia, Institut Català d'Oncologia, Grup d'Epidemiologia Descriptiva, Genètica i Prevenció del Càncer de Girona-IDIBGI, 17005, Girona, Spain.
Jaume GalceranRegistre de Càncer de Tarragona, Servei d'Epidemiologia I Prevenció del Càncer, Hospital Universitari Sant Joan de Reus, IISPV, Reus, Spain.
Josep Maria BorràsPla Director d'Oncologia - Institut Català d'Oncologia, Av Gran Vía 199-203, 08908, L'Hospitalet de Llobregat (Barcelona), Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTobacco smoke is a well-established carcinogen associated with malignancies across a broad spectrum of organ sites. This study quantifies the 2024 burden of smoking-related cancer in Catalonia (Spain) by estimating smoking-Attributable Cases under a Bayesian framework (AC

methodsWe analyzed regional cancer incidence data from 2010 to 2019 and projected incidence for 2020-2024. The impact of tobacco smoke in 2024 was calculated employing a Bayesian estimate of the Population Attributable Fraction (PAF

resultsBetween 2010 and 2024, the number of tobacco-related cancer cases increased at a higher rate in women (from 6005 to 7167: 1.8%) than in men (from 12,774 to 14,130: 1.1%). In women, the increase in lung cancer cases was the most pronounced, rising 4%, from 830 to 1245 cases per year. In 2024, 8330 cancer cases (19.4% of all diagnoses) were attributable to smoking. In men, PAF

conclusionsUnder a theoretical scenario of smoking elimination, the lifetime cancer risk would shift from 1 in 2 to 1 in 3 for men, and from 1 in 3 to 1 in 3.4 for women. Ongoing prevention strategies must be supported: (i) advancing smoke- and aerosol-free legislation will protect future generations, and (ii) actively promoting primary care-led cessation programs is required.

Indexed as

Bayesian modelingCancer burdenCancer epidemiologyPopulation attributable fractionTobacco smoking

Identifiers

PMID42402534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.